Literature DB >> 12141831

Diabetes mellitus during interferon therapy for chronic viral hepatitis.

Ali Mofredj1, Mehran Howaizi, Denis Grasset, Henri Licht, Sylvie Loison, Bruno Devergie, Renato Demontis, Jean-François Cadranel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12141831     DOI： 10.1023/a:1015852110353

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  45 in total

1.  Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C.

Authors:  A Bhatti; T J McGarrity; R Gabbay
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

2.  Caution is required with interferon alpha as a potential treatment for type I diabetes.

Authors:  P E Beales; P Pozzilli
Journal:  Diabetologia       Date:  1999-03       Impact factor: 10.122

3.  Diabetes mellitus and interferon therapy.

Authors:  L Frankart; D Lejeune; J Donckier
Journal:  Diabet Med       Date:  1997-05       Impact factor: 4.359

4.  High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study.

Authors:  S Grimbert; P Valensi; C Lévy-Marchal; G Perret; J P Richardet; C Raffoux; J C Trinchet; M Beaugrand
Journal:  Gastroenterol Clin Biol       Date:  1996

5.  Onset of insulin-dependent diabetes mellitus after interferon-alfa therapy for hairy cell leukaemia.

Authors:  A P Guerci; B Guerci; C Lévy-Marchal; J Ongagna; O Ziegler; H Candiloros; O Guerci; P Drouin
Journal:  Lancet       Date:  1994-05-07       Impact factor: 79.321

6.  Ingested interferon alpha suppresses type I diabetes in non-obese diabetic mice.

Authors:  S A Brod; M Malone; S Darcan; M Papolla; L Nelson
Journal:  Diabetologia       Date:  1998-10       Impact factor: 10.122

7.  Alpha-interferon inhibits the development of diabetes in NOD mice.

Authors:  D O Sobel; B Ahvazi
Journal:  Diabetes       Date:  1998-12       Impact factor: 9.461

8.  Insulin sensitivity, insulin secretion and glucose effectiveness in diabetic and non-diabetic cirrhotic patients.

Authors:  Y T Kruszynska; D S Harry; R N Bergman; N McIntyre
Journal:  Diabetologia       Date:  1993-02       Impact factor: 10.122

9.  [Transient insulin-dependent diabetes mellitus with alpha-interferon therapy in chronic active hepatitis].

Authors:  U Gross; E Seifert
Journal:  Z Gastroenterol       Date:  1993-10       Impact factor: 2.000

10.  Effect of interferon on glucose tolerance and insulin sensitivity.

Authors:  V A Koivisto; R Pelkonen; K Cantell
Journal:  Diabetes       Date:  1989-05       Impact factor: 9.461
View more
  10 in total

Review 1.  Hepatitis C virus infection and type 1 and type 2 diabetes mellitus.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Dilia Giuggioli; Andrea Di Domenicantonio; Ilaria Ruffilli; Alda Corrado; Silvia Fabiani; Santino Marchi; Clodoveo Ferri; Ele Ferrannini; Poupak Fallahi
Journal:  World J Diabetes       Date:  2014-10-15

Review 2.  Hepatitis C virus induced insulin resistance impairs response to anti viral therapy.

Authors:  Abdel-Rahman El-Zayadi; Mahmoud Anis
Journal:  World J Gastroenterol       Date:  2012-01-21       Impact factor: 5.742

3.  Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C.

Authors:  Jee-Fu Huang; Chao-Kuan Huang; Ming-Lung Yu; Chia-Yen Dai; Chung-Feng Huang; Wei-Wen Hung; Ming-Lun Yeh; Meng-Hsuan Hsieh; Jeng-Fu Yang; Ming-Yen Hsieh; Zu-Yau Lin; Shinn-Chern Chen; Shun-Sheng Wu; Wan-Long Chuang
Journal:  Hepatol Int       Date:  2011-08-18       Impact factor: 6.047

Review 4.  Interferon therapy in hepatitis C leading to chronic type 1 diabetes.

Authors:  Taiba Zornitzki; Stephen Malnick; Lyudmila Lysyy; Hilla Knobler
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

5.  Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B.

Authors:  Yuan-Yuan Lv; Bing-Yin Shi; Hui Guo
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

6.  Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C.

Authors:  Aspasia S Soultati; Spyridon P Dourakis; Alexandra Alexopoulou; Melanie Deutsch; Athanasios J Archimandritis
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

7.  Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review.

Authors:  Reiko Oka; Naoki Hiroi; Rika Shigemitsu; Mariko Sue; Yasuo Oshima; Mayumi Yoshida-Hiroi
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2011-08-23

8.  Adipose tissue deficiency and chronic inflammation in diabetic Goto-Kakizaki rats.

Authors:  Bai Xue; Siddharth Sukumaran; Jing Nie; William J Jusko; Debra C Dubois; Richard R Almon
Journal:  PLoS One       Date:  2011-02-25       Impact factor: 3.240

9.  Diabetes disease progression in Goto-Kakizaki rats: effects of salsalate treatment.

Authors:  Xi Wang; Debra C DuBois; Yanguang Cao; William J Jusko; Richard R Almon
Journal:  Diabetes Metab Syndr Obes       Date:  2014-08-01       Impact factor: 3.168

10.  Effects of High-Fat Feeding on Skeletal Muscle Gene Expression in Diabetic Goto-Kakizaki Rats.

Authors:  Jing Nie; Debra C DuBois; Bai Xue; William J Jusko; Richard R Almon
Journal:  Gene Regul Syst Bio       Date:  2017-05-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.